Barton Shane: insider trades.
Barton Shane reported 10 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 2 sales ($1.6M), across 1 company.
- Transactions
- 10
- Purchases (P)
- 0
- Sales (S)
- 2
- Companies
- 1
- Name as filed
- Barton Shane
Companies
| Company | Relationship | Transactions |
|---|---|---|
| BioAge Labs, Inc. (BIOA) | Officer · Principal Accounting Officer | 10 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | BioAge Labs, Inc. | M | 4,000 | $8.39 | 8,290 | Form 4 |
| 2026-06-30 | BioAge Labs, Inc. | M | 4,065 | $4.3 | 12,355 | Form 4 |
| 2026-06-30 | BioAge Labs, Inc. | M | 7,861 | $4.38 | 20,216 | Form 4 |
| 2026-06-30 | BioAge Labs, Inc. | S | 20,216 | $25.19 | 0 | Form 4 |
| 2026-06-30 | BioAge Labs, Inc. | M | 4,290 | $10.85 | 4,290 | Form 4 |
| 2026-06-29 | BioAge Labs, Inc. | M | 7,261 | $8.39 | 19,194 | Form 4 |
| 2026-06-29 | BioAge Labs, Inc. | M | 8,958 | $4.3 | 28,152 | Form 4 |
| 2026-06-29 | BioAge Labs, Inc. | M | 14,198 | $4.38 | 42,350 | Form 4 |
| 2026-06-29 | BioAge Labs, Inc. | S | 42,350 | $25.21 | 0 | Form 4 |
| 2026-06-29 | BioAge Labs, Inc. | M | 9,301 | $10.85 | 11,933 | Form 4 |
Questions
What stock did Barton Shane buy or sell?
Barton Shane reported 10 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 2 sales ($1.6M), across 1 company.
Is Barton Shane the same person as other filers with this name?
This page covers SEC CIK 1836297 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/barton-shane-1836297.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.